JIANGSU YAHONG MEDITECH CO., LTD. Financials Jiangsu Yahong Meditech Co., Ltd.
Equities
688176
CNE100005XW0
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.38 CNY | +1.59% |
|
-0.78% | -40.82% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 6,412 | 6,145 | 3,637 | - | - |
| Enterprise Value (EV) 1 | 6,412 | 6,145 | 3,637 | 3,637 | 3,637 |
| P/E ratio | -26.2 x | -15.4 x | -10.1 x | -10.8 x | -15.2 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 245,690 x | 447 x | 34.6 x | 12.1 x | 6.03 x |
| EV / Revenue | 245,690 x | 447 x | 34.6 x | 12.1 x | 6.03 x |
| EV / EBITDA | -27.7 x | -15.7 x | -9.75 x | -11.5 x | -20.5 x |
| EV / FCF | - | -12.3 x | -7.88 x | -6.74 x | -6.89 x |
| FCF Yield | - | -8.13% | -12.7% | -14.8% | -14.5% |
| Price to Book | 2.31 x | 2.57 x | 1.79 x | 2.15 x | 2.5 x |
| Nbr of stocks (in thousands) | 570,000 | 570,000 | 570,000 | - | - |
| Reference price 2 | 11.25 | 10.78 | 6.380 | 6.380 | 6.380 |
| Announcement Date | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.0261 | 13.75 | 105 | 301.5 | 603.5 |
| EBITDA 1 | - | -231.5 | -390.8 | -373 | -315 | -177 |
| EBIT 1 | - | -247.6 | -404 | -363 | -337 | -243 |
| Operating Margin | - | -948,479.31% | -2,937.5% | -345.71% | -111.77% | -40.27% |
| Earnings before Tax (EBT) 1 | - | -245.3 | -401.5 | -360 | -335 | -241 |
| Net income 1 | -238.4 | -246.6 | -400.4 | -359 | -334 | -240 |
| Net margin | - | -944,803.1% | -2,911.55% | -341.9% | -110.78% | -39.77% |
| EPS 2 | -0.5200 | -0.4300 | -0.7000 | -0.6300 | -0.5900 | -0.4200 |
| Free Cash Flow 1 | - | - | -499.8 | -461.7 | -539.6 | -527.8 |
| FCF margin | - | - | -3,634.19% | -439.75% | -178.98% | -87.46% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 24/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -500 | -462 | -540 | -528 |
| ROE (net income / shareholders' equity) | - | -8.53% | -15.5% | -17.7% | -19.7% | -16.5% |
| ROA (Net income/ Total Assets) | - | -8.26% | -14.5% | -16% | -17.2% | -11.2% |
| Assets 1 | - | 2,986 | 2,756 | 2,244 | 1,942 | 2,143 |
| Book Value Per Share 2 | - | 4.860 | 4.190 | 3.560 | 2.970 | 2.550 |
| Cash Flow per Share 2 | - | -0.4200 | -0.7000 | -0.9600 | - | - |
| Capex 1 | - | 26.6 | 102 | 37 | 163 | 160 |
| Capex / Sales | - | 101,955.75% | 738.98% | 35.24% | 53.9% | 26.51% |
| Announcement Date | 24/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.38
CNY
Average target price
12.28
CNY
Spread / Average Target
+92.55%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.82% | 504M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- 688176 Stock
- Financials Jiangsu Yahong Meditech Co., Ltd.
